MORE THAN 100 TECHNOLOGIES DEVELOPED ACROSS DIFFERENT THERAPIES IN LESS THAN 15 YEARS
​
OUR INNOVATIONS
Myval
-
Low device related mortality
-
Low incidence of stroke
-
Low pacemaker rate
​
Myval is a Hybrid honeycomb cell design Transcatheter heart valve which is CE approved. Its Alternating V-folds & vertical connectors give Myval THV a unique “Zebra Crossing” appearance on fluoro for ease of positioning. MyVal- 1 study successfully system demonstrated excellent clinical and hemodynamic outcomes at 6-month
​
* 6 month outcome data presented by Dr. Ravinder Singh Rao at PCR e- course 2020
.png)
MeRes100
Meril has developed the first 100 micron fully bioresorbably vascular scaffold MeRes100, which is expected to be launched globally soon. MeRes100 is a 2nd generation bioresorbable technology with low strut thickness of 100 μm leading to lower crossing profile for ease of delivery and early endothelialization.
​
​
​
​
​
​
.png)
Evermine50
Evermine50 is a Everolimus Eluting Coronary Stent System with ultrathin strut thickness of 50 μm. Ultra-thin struts help in faster endothelialization, early vascular healing, less vessel injury, less inflammation, and avoids thrombus formation compared to thicker struts.
​
​
​
​
​
​
​
​
​
Biomime Morph
Biomime Morph is the world's first tapered Sirolimus Eluting Coronary Stent System. This next generation DES has a novel hybrid design with closed cells & open cells and comes with a thin 65 µm strut thickness.
​
​
​
​
​
​
​
​
​
Why Partner
​
with Meril
RESEARCH AND DEVELOPMENT
-
At Meril, our continuous goal is to identify unmet clinical needs and churn out relevant devices in quick turnaround cycles.
-
Innovation ingrained in Meril’s DNA with a dedicated 150 strong R&D team working on a robust pipeline.
-
Over 150 technologies spanning multiple therapies like interventional cardiology, orthopedics, endo-surgery and diagnostics developed in less than 15 years.
-
Meril R&D Foundry is an eclectic, heterogeneous team comprising doctors,biomedical, mechanical, chemical engineers, material science experts of polymer science, chemistry, pharmaceuticals and biotechnology. It hosts more than 150 R&D personnel with cross functional relationship.
INFRASTRUCTURE
-
Meril Park sprawls 250,000 square feet. It is our dedicated manufacturing and R&D facility for in-vitro diagnostic, orthopaedic, endo-surgery and cardio vascular solutions.
-
Meril’s cardio vascular manufacturing comprises 40,000 square feet of built-up area along with 10,000 square feet of clean rooms. Our manufacturing facilities strictly adhere to cGMP guidelines, are ISO 13485:2003 certified and are DCGI approved.
-
Manufacturing facilities approved by US-FDA, China-PMDA, CDSCO and other major global regulators
-
Over 44 clinical studies covering 10,500+ patients completed or underway in India, Europe, Brazil, China and beyond.
PLACING INDIA ON GLOBAL INNOVATION MAP
-
Company that has presence in 140+ countries.
-
Meril Vascular Intervention has developed new concepts in engineering employing novel designs with a cleverly iterated diverse portfolio including devices ranging from drug eluting stents, bioresorbable scaffolds, balloon catheters, peripheral vascular and transcatheter aortic valve replacement system (TAVR).
-
Scientific engagement of a global audience of healthcare professionals at prestigious international cardiology forums like TCT, EuroPCR & PCR London Valves.
FROST & SULLIVAN AWARD
-
Meril’s constant endeavour to focus on innovation and R&D has led to a wide range of path breaking products.
-
Such exemplary attention to indigenous innovation and a truly global presence alongside a strong ‘Make In India’ focus, has been recently recognized by Frost & Sullivan lately, which declared Meril as the Indian Cardiac Implant Company of the year in 2019.
-
Such accolades encourage us to continue pursuing excellence in R&D and state-of-the art manufacturing, helping us serve millions of patients around the world.
TEAM
-
It is through the hard work of each and every one of our employees that we are able to continue to provide innovative solutions for people fighting cardiovascular diseases.
-
Our team is committed to making a difference to HCPs and Patients LIVES.
-
Click here to listen, Mr Sanjeev Bhatt speak on Meril’s innovation journey.
